Market Size of Global Endometriosis Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.30 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Endometriosis Treatment Market Analysis
The Endometriosis Treatment Market is expected to register a CAGR of 5.3% over the forecast period, 2022-2027.
COVID-19 pandemic had a substantial impact on patients with chronic disease conditions like endometriosis. The strict lockdowns and government regulations intended to slow down the spread of COVID-19 resulted in a decrease in demand for products across all segments. In wake of the COVID-19 outbreak, women with endometriosis are particularly exposed to the risk of post-traumatic stress disorder during the SARS-CoV-2 pandemic, especially if they are older or have higher levels of anxiety.
As per the articles published in October 2021 titled 'Effects of the SARS-CoV-2 pandemic on women affected by endometriosis in the National Library of Medicine, 68.8% were quite extremely worried about not being able to access gynecologic care during this period, thus, the COVID-19 had a significant impact on the endometriosis treatment market.
According to World Health Organization, in 2021 endometriosis affects roughly 10% (190 million) of reproductive-age women and girls globally. Further, the rise in the prevalence of endometriosis, growing awareness of the disease, and growing need for early diagnosis are among the major factors driving the growth of the studied market. Such factors are likely to boost the adoption of the endometriosis treatment market, thereby contributing to the studied market growth.
In addition, growing awareness and research and development funding by major players in the market are positively affecting the growth of the studied market. For instance, in February 2021 the DBT Wellcome India Alliance is supporting a major national research project 'Endometriosis Clinical and Genetic Research in India (ECGRI)' that aims to broaden understanding of the clinical phenotypes and genetic risks associated with endometriosis. Additionally, in February 2021, the European Union is supporting a major international research and innovation project that aims to improve the treatment and quality of life of those with endometriosis.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period. However, the high cost of endometriosis treatment is likely to impede the market growth.
Endometriosis Treatment Industry Segmentation
As per the scope of the report, endometriosis is a disease where tissue similar to the lining of the uterus grows outside the uterus, causing pain and/or infertility. The Endometriosis Treatment Market is segmented by Type (Superficial Peritoneal Endometriosis, Endometriomas, Deeply Infiltrating Endometriosis, and Other Types), By Treatment Type (Pain Medication and Hormone Therapy), End User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Type | |
| Superficial Peritoneal Endometriosis | |
| Endometriomas | |
| Deeply Infiltrating Endometriosis | |
| Other Types |
| By Treatment Type | |
| Pain Medication | |
| Hormone Therapy |
| By End User | |
| Hospitals | |
| Specialty Clinics | |
| Other End Users |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Endometriosis Treatment Market Size Summary
The Endometriosis Treatment Market is poised for growth, driven by increasing awareness and the rising prevalence of endometriosis among reproductive-age women globally. The market is experiencing a positive trajectory due to factors such as the need for early diagnosis and the ongoing research and development efforts by key industry players. The COVID-19 pandemic significantly impacted the market, as it disrupted access to gynecologic care and heightened psychological stress among affected women. Despite these challenges, the market is expected to expand, supported by initiatives like the DBT Wellcome India Alliance's research project and European Union's international research efforts aimed at improving treatment and quality of life for endometriosis patients. However, the high cost of treatment remains a potential barrier to market growth.
North America is anticipated to lead the Endometriosis Treatment Market, attributed to the availability of advanced medical products, heightened awareness, and a significant prevalence of the condition in the region. The market's growth is further bolstered by strategic collaborations and product launches, such as the FDA-approved MYFEMBREE by Myovant Sciences and Pfizer Inc. The market is characterized by its fragmented nature, with numerous global and regional players focusing on innovative product development. Key companies like Bayer AG, Pfizer Inc., and AbbVie Inc. are actively contributing to the market's expansion through research and strategic agreements, such as ObsEva SA's licensing deal with Theramex for linzagolix, a potential treatment for endometriosis-associated pain.
Global Endometriosis Treatment Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Driver
-
1.2.1 Rise in the Prevalence of Endometriosis
-
1.2.2 Growing Awareness of the Disease and Growing Need of Early Diagnosis
-
-
1.3 Market Restraints
-
1.3.1 High Cost Associated With The Treatment
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Type
-
2.1.1 Superficial Peritoneal Endometriosis
-
2.1.2 Endometriomas
-
2.1.3 Deeply Infiltrating Endometriosis
-
2.1.4 Other Types
-
-
2.2 By Treatment Type
-
2.2.1 Pain Medication
-
2.2.2 Hormone Therapy
-
-
2.3 By End User
-
2.3.1 Hospitals
-
2.3.2 Specialty Clinics
-
2.3.3 Other End Users
-
-
2.4 Geography
-
2.4.1 North America
-
2.4.1.1 United States
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia-Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Middle-East and Africa
-
2.4.4.1 GCC
-
2.4.4.2 South Africa
-
2.4.4.3 Rest of Middle-East and Africa
-
-
2.4.5 South America
-
2.4.5.1 Brazil
-
2.4.5.2 Argentina
-
2.4.5.3 Rest of South America
-
-
-
Global Endometriosis Treatment Market Size FAQs
What is the current Global Endometriosis Treatment Market size?
The Global Endometriosis Treatment Market is projected to register a CAGR of 5.30% during the forecast period (2024-2029)
Who are the key players in Global Endometriosis Treatment Market?
Bayer AG, Pfizer Inc., AbbVie Inc. , Lannett and Teva Pharmaceutical Industries are the major companies operating in the Global Endometriosis Treatment Market.
